MCID: ADN009
MIFTS: 49

Adenosquamous Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 15 17 70
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 44
Carcinoma Adenosquamous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 44 D018196
NCIt 50 C3727
SNOMED-CT 67 403902008
UMLS 70 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to esophageal adenosquamous carcinoma and adenosquamous lung carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Doxorubicin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include cervix, pancreas and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 650)
# Related Disease Score Top Affiliating Genes
1 esophageal adenosquamous carcinoma 32.5 TP53 KRT7 KRT5 CEACAM5
2 adenosquamous lung carcinoma 32.3 PIK3CA KRAS EGFR
3 tubular adenocarcinoma 31.0 MUC1 KRT7 EGFR CEACAM5
4 subareolar duct papillomatosis 30.7 KRT8 KRT7 KRT5
5 cervical adenocarcinoma 30.7 TP53 KRT7 KRAS EGFR CEACAM7 CEACAM5
6 pancreatic ductal adenocarcinoma 30.7 TP53 SMAD4 MUC1 KRAS EGFR CDKN2A
7 gallbladder adenocarcinoma 30.7 TP53 PIK3CA EGFR
8 cystadenoma 30.7 SERPINA3 MUC1 KRT7 CEACAM5
9 appendix adenocarcinoma 30.6 SMAD4 KRT7 KRAS
10 signet ring cell adenocarcinoma 30.6 TP53 MUC1 KRT7 KRAS CEACAM5
11 gallbladder cancer 30.6 TP53 PIK3CA KRAS EGFR CEACAM5 CDKN2A
12 intrahepatic cholangiocarcinoma 30.6 TP53 SMAD4 MUC4 MUC1 KRT7 KRT19
13 squamous cell papilloma 30.6 TP53 CDKN2A
14 leukoplakia of penis 30.5 KRT7 CEACAM5
15 mature teratoma 30.5 TP53 KRT7 KRAS CEACAM5
16 bile duct cysts 30.5 KRT7 KRT19 KRAS CEACAM5
17 klatskin's tumor 30.5 TP53 KRT7 KRT19 CEACAM5
18 oral cancer 30.5 TP53 KRT19 EGFR CDKN2A
19 gallbladder squamous cell carcinoma 30.5 KRT5 CEACAM5
20 skin benign neoplasm 30.4 TP63 SERPINA3 KRT7 KRT5
21 bile duct cystadenocarcinoma 30.4 MUC1 KRT7 CEACAM5
22 pancreatic adenocarcinoma 30.4 TP53 SMAD4 PIK3CA MUC4 KRAS EGFR
23 mucoepidermoid esophageal carcinoma 30.4 TP53 KRT5 CEACAM5
24 barrett esophagus 30.4 TP53 SMAD4 KRT7 CDKN2A AR
25 gastric squamous cell carcinoma 30.3 SERPINA3 KRT7 KRT5
26 cervical cancer 30.3 TP63 TP53 SMAD4 PIK3CA KRT19 CDKN2A
27 gastric adenocarcinoma 30.3 TP53 SMAD4 PIK3CA KRAS CEACAM5 CDKN2A
28 spindle cell sarcoma 30.3 SERPINA3 MUC1 KRT7
29 necrotizing sialometaplasia 30.3 TP63 TP53 KRT7 KRT5
30 lung squamous cell carcinoma 30.2 TP63 TP53 PIK3CA KRT19 KRAS EGFR
31 breast metaplastic carcinoma 30.2 MAML2 KRT7 KRT5 EGFR
32 adenoid squamous cell carcinoma 30.2 KRT8 KRT7 KRT5 KRT19
33 papilloma 30.2 TP63 TP53 KRT8 KRT7 KRT5 KRAS
34 syringocystadenoma papilliferum 30.2 SERPINA3 MUC1 KRT19 KRAS
35 squamous cell carcinoma 30.2 TP63 TP53 SMAD4 PIK3CA MUC1 KRT7
36 acinar cell carcinoma 30.2 TP53 SMAD4 SERPINA3 KRT7
37 endometrial adenocarcinoma 30.2 TP53 MUC1 KRT7 KRAS EGFR CDKN2A
38 cystic teratoma 30.2 TP53 NKX2-1 KRT7 KRAS CDKN2A
39 lymphoepithelioma-like carcinoma 30.1 MUC1 KRT8 KRT7 KRT19 EGFR
40 secretory meningioma 30.1 SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
41 in situ carcinoma 30.1 TP53 SERPINA3 PIK3CA MUC1 KRT8 KRT5
42 adenocarcinoma in situ 30.1 KRT7 KRAS EGFR CEACAM5 CDKN2A
43 large cell neuroendocrine carcinoma 30.1 NKX2-1 KRT7 EGFR
44 cystadenocarcinoma 30.1 TP53 SERPINA3 PIK3CA MUC1 KRT7 CEACAM5
45 papillary squamous carcinoma 30.1 KRT7 KRT5 EGFR CEACAM5 CDKN2A
46 carcinosarcoma 30.1 TP53 PIK3CA MUC1 KRT7 KRAS EGFR
47 cholangiocarcinoma 30.0 TP53 SMAD4 PIK3CA MUC4 MUC1 KRT8
48 endocervical adenocarcinoma 30.0 TP53 PIK3CA MUC1 KRT7 CEACAM5 CDKN2A
49 cervical squamous cell carcinoma 30.0 TP63 TP53 PIK3CA KRT8 KRAS EGFR
50 teratoma 30.0 TP53 NKX2-1 KRT7 KRAS CEACAM5 CDKN2A

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 EGFR KRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 9.64 EGFR KRAS MUC1 PIK3CA
3 Decreased viability GR00055-A-3 9.64 KRAS
4 Decreased viability GR00106-A-0 9.64 KRAS
5 Decreased viability GR00221-A-1 9.64 EGFR KRAS PIK3CA
6 Decreased viability GR00221-A-2 9.64 KRAS PIK3CA
7 Decreased viability GR00221-A-4 9.64 EGFR PIK3CA
8 Decreased viability GR00249-S 9.64 MUC1
9 Decreased viability GR00301-A 9.64 KRAS
10 Decreased viability GR00381-A-1 9.64 KRAS
11 Decreased viability GR00402-S-2 9.64 PIK3CA
12 Decreased cell migration GR00055-A-1 9.13 CTSD
13 Decreased cell migration GR00055-A-3 9.13 EGFR PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 AR CDKN2A CTSD EGFR KRAS KRT19
2 cardiovascular system MP:0005385 10.3 AR CDKN2A EGFR KRAS KRT19 KRT8
3 digestive/alimentary MP:0005381 10.3 AR CDKN2A CTSD EGFR KRAS KRT19
4 growth/size/body region MP:0005378 10.29 AR CDKN2A CTSD EGFR KRAS KRT19
5 endocrine/exocrine gland MP:0005379 10.24 AR CDKN2A CTSD EGFR KRAS KRT19
6 immune system MP:0005387 10.23 AR CDKN2A CTSD EGFR KRAS KRT19
7 embryo MP:0005380 10.21 AR CDKN2A EGFR KRAS KRT19 KRT8
8 integument MP:0010771 10.21 AR CDKN2A CTSD EGFR KRAS KRT19
9 craniofacial MP:0005382 10.14 AR EGFR KRAS KRT19 KRT5 SMAD4
10 liver/biliary system MP:0005370 9.97 AR CDKN2A EGFR KRAS KRT19 KRT8
11 neoplasm MP:0002006 9.96 AR CDKN2A EGFR KRAS KRT19 NKX2-1
12 limbs/digits/tail MP:0005371 9.95 AR EGFR KRAS KRT5 SMAD4 TP53
13 muscle MP:0005369 9.92 AR CDKN2A EGFR KRAS PIK3CA SMAD4
14 no phenotypic analysis MP:0003012 9.76 CDKN2A EGFR KRAS KRT19 NKX2-1 PIK3CA
15 reproductive system MP:0005389 9.7 AR CDKN2A EGFR KRAS KRT19 KRT8
16 skeleton MP:0005390 9.32 AR CDKN2A EGFR KRAS KRT19 NKX2-1

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Fluorouracil Approved Phase 3 51-21-8 3385
7
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
8
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
9
leucovorin Approved Phase 3 58-05-9 6006
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
12
Tirapazamine Investigational Phase 3 27314-97-2
13
Liposomal doxorubicin Phase 3 31703
14 Hematinics Phase 3
15 Epoetin alfa Phase 3 113427-24-0
16 Antimetabolites Phase 3
17 Antidotes Phase 3
18 Nutrients Phase 3
19 topoisomerase I inhibitors Phase 3
20 Trace Elements Phase 3
21 Micronutrients Phase 3
22 Protective Agents Phase 3
23 Vitamins Phase 3
24 Calcium, Dietary Phase 3
25 Hormones Phase 3
26 Tubulin Modulators Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28 Antimitotic Agents Phase 3
29 Mitogens Phase 3
30 Antibodies Phase 3
31 Immunoglobulins Phase 3
32 Protein Kinase Inhibitors Phase 3
33
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
34 Antibodies, Monoclonal Phase 3
35 insulin Phase 3
36 Insulin, Globin Zinc Phase 3
37
Calcium Nutraceutical Phase 3 7440-70-2 271
38
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
39
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
40
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
43
Metformin Approved Phase 2 657-24-9 4091 14219
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Lenograstim Approved, Investigational Phase 2 135968-09-1
46
nivolumab Approved Phase 2 946414-94-4
47
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
2 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
4 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
6 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Completed NCT01365156 Phase 3
7 A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer Recruiting NCT04340141 Phase 3 Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
8 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Recruiting NCT01101451 Phase 3 Cisplatin
9 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
10 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
11 Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
12 Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
13 Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
14 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
15 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
16 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
17 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
18 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
19 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
20 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
21 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
22 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
23 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
24 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
25 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
26 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
27 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
28 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
29 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
30 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
31 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
32 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
33 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
34 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
35 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
36 A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer Completed NCT02921269 Phase 2 Atezolizumab
37 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
38 The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial Recruiting NCT02394652 Phase 2 Metformin;Cisplatin;FAZA
39 Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma Recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin
40 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
41 A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer Active, not recruiting NCT02257528 Phase 2
42 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
43 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
44 Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma: A Multicenter, Open-label, Randomized, Control Phase II Study(ARISE) Not yet recruiting NCT04354961 Phase 2 Almonertinib;Paclitaxel and carboplatin
45 A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) Not yet recruiting NCT03834571 Phase 2 Carboplatin;Cisplatin;Paclitaxel
46 A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen Suspended NCT02133196 Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
47 A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas Terminated NCT02868892 Phase 2 Pemetrexed
48 A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck Terminated NCT00570674 Phase 1, Phase 2 Abraxane;Erbitux;Carboplatin
49 A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer Terminated NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
50 A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma Withdrawn NCT01301612 Phase 2 Nimotuzumab;Cisplatin;Cisplatin

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

40
Cervix, Pancreas, Colon, Lymph Node, Prostate, Breast, Thyroid

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 1865)
# Title Authors PMID Year
1
Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. 61 54
19859629 2009
2
Large cell carcinoma of the lung: an endangered species? 54 61
19444077 2009
3
Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. 61 54
19514842 2009
4
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. 61 54
19563658 2009
5
Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. 54 61
19278431 2009
6
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. 54 61
18992960 2009
7
Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). 54 61
18836809 2008
8
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. 61 54
17581404 2007
9
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. 61 54
17186532 2007
10
Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. 61 54
17090193 2006
11
The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. 54 61
17036524 2006
12
Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. 61 54
16187277 2006
13
Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. 61 54
15864702 2005
14
Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. 61 54
15016319 2004
15
Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. 54 61
14610320 2003
16
Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. 61 54
12558872 2003
17
Neuroendocrine marker expression in cervical carcinomas of non-small cell type. 61 54
12352185 2002
18
Primary adenosquamous carcinoma of the liver which produces granulocyte-colony-stimulating factor and parathyroid hormone related protein: association with leukocytosis and hypercalcemia. 54 61
11506305 2001
19
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 61 54
11381365 2001
20
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 61 54
11006578 2000
21
EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. 54 61
9588219 1998
22
Different angiogenic pathways in human cervical cancers. 54 61
9454658 1998
23
Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. 54 61
7671236 1995
24
Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. 54 61
7654016 1995
25
Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. 61 54
7736397 1995
26
Hypercalcaemia in a patient with fatal adenosquamous carcinoma of the colon. 54 61
8107631 1994
27
Cathepsin-D expression in cervical carcinoma and its prognostic significance. 61 54
8322451 1993
28
Immunocytologic diagnosis of small-cell lung cancer in imprint smears. 54 61
1656682 1991
29
[A parathyroid hormone related protein (PTHrP) implicated in hypercalcemia associated with malignancy: research of the PTHrP for novel hormonal tumor marker]. 54 61
2348564 1990
30
Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. 61
33387918 2021
31
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. 61
33794207 2021
32
Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. 61
33771396 2021
33
Cervical cancer in women under 30 years of age in Norway: a population-based cohort study. 61
33736628 2021
34
The baseline recurrence risk of patients with intermediate-risk cervical cancer. 61
33752280 2021
35
Cervical conization and lymph node assessment for early stage low-risk cervical cancer. 61
33649012 2021
36
Molecular mechanisms of An-Chuan Granule for the treatment of asthma based on a network pharmacology approach and experimental validation. 61
33645621 2021
37
PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions. 61
33773917 2021
38
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. 61
33802174 2021
39
Adenosquamous carcinoma: An aggressive histologic sub-type of colon cancer with poor prognosis. 61
32862977 2021
40
Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort. 61
33787974 2021
41
Characteristics and survival prognosis of patients with pure squamous cell carcinoma of the gallbladder. 61
33236449 2021
42
Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis. 61
33685817 2021
43
Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience. 61
33190924 2021
44
Updates on World Health Organization classification and staging of esophageal tumors: implications for future clinical practice. 61
33157124 2021
45
Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. 61
33622577 2021
46
Esophageal superficial adenosquamous carcinoma resected by endoscopic submucosal dissection: A rare case report. 61
33644200 2021
47
NTRK fusion-positive colorectal cancer in Japanese population. 61
33631044 2021
48
Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis-Lessons learned from a 12-year analysis of the National Cancer Database. 61
33482684 2021
49
Pancreatic panniculitis in a patient with pancreatic adenosquamous carcinoma. 61
33124679 2021
50
An Australian, single-centre study of surgical management outcomes for early-stage cervical cancer. 61
33176013 2021

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 SMAD4 PIK3CA KRT8 KRT7 KRT5 KRT19
2
Show member pathways
12.66 TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
3
Show member pathways
12.65 TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
4
Show member pathways
12.64 TP53 PIK3CA KRAS EGFR CDKN2A
5
Show member pathways
12.63 PIK3CA KRT19 KRAS EGFR CTSD
6
Show member pathways
12.56 TP63 TP53 PIK3CA KRAS CTSD CDKN2A
7 12.48 MUC1 KRT8 KRT7 KRT5 KRT19
8 12.42 TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
9
Show member pathways
12.29 PIK3CA MUC1 KRAS EGFR
10
Show member pathways
12.28 TP53 PIK3CA EGFR AR
11 12.27 TP53 PIK3CA KRAS EGFR
12 12.26 TP53 PIK3CA KRAS CDKN2A
13 12.23 TP63 TP53 PIK3CA KRAS EGFR CDKN2A
14 12.22 TP53 SMAD4 PIK3CA KRAS CDKN2A
15
Show member pathways
12.19 TP53 PIK3CA KRAS EGFR AR
16 12.15 TP53 SMAD4 KRAS EGFR
17 12.11 TP53 PIK3CA KRAS CDKN2A
18
Show member pathways
12.04 SMAD4 PIK3CA KRAS EGFR
19 12.01 TP63 TP53 EGFR CTSD
20 11.94 TP53 PIK3CA KRAS CTSD
21 11.91 TP53 SMAD4 KRAS EGFR AR
22
Show member pathways
11.9 TP53 SMAD4 PIK3CA MUC1 KRAS EGFR
23 11.89 TP53 KRAS EGFR CDKN2A
24
Show member pathways
11.87 KRT8 KRT7 KRT5 KRT19
25 11.7 TP53 PIK3CA CDKN2A
26 11.6 TP53 KRAS EGFR CDKN2A
27 11.55 TP53 PIK3CA KRAS EGFR
28 11.52 TP53 EGFR CDKN2A
29 11.41 TP53 SMAD4 CTSD
30 11.3 TP53 KRT8 KRT19
31 11.21 SMAD4 KRAS EGFR
32 11.13 PIK3CA KRAS EGFR
33 11.08 TP53 SMAD4 PIK3CA KRAS CDKN2A
34
Show member pathways
11.01 TP63 TP53 CDKN2A

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 SERPINA3 MUC4 MUC1 KRT8 KRT7 KRT5
2 intermediate filament GO:0005882 9.26 KRT8 KRT7 KRT5 KRT19

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 TP53 NKX2-1 KRAS CDKN2A AR
2 keratinization GO:0031424 9.67 KRT8 KRT7 KRT5 KRT19
3 Ras protein signal transduction GO:0007265 9.58 TP53 KRAS CDKN2A
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 TP63 TP53 SMAD4 NKX2-1 MAML2 EGFR
5 cornification GO:0070268 9.46 KRT8 KRT7 KRT5 KRT19
6 Leydig cell differentiation GO:0033327 9.43 NKX2-1 AR
7 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.32 TP53 MUC1
8 cell differentiation involved in embryonic placenta development GO:0060706 9.26 KRT8 KRT19
9 positive regulation of transcription, DNA-templated GO:0045893 9.17 TP63 TP53 SMAD4 NKX2-1 EGFR CDKN2A

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.72 TP63 TP53 SMAD4 EGFR AR
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.55 TP63 TP53 SMAD4 NKX2-1 AR
3 RNA polymerase II transcription factor binding GO:0001085 9.43 TP53 SMAD4 AR
4 p53 binding GO:0002039 9.26 TP63 TP53 MUC1 CDKN2A
5 MDM2/MDM4 family protein binding GO:0097371 8.8 TP63 TP53 CDKN2A

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....